Details of the Drug Reposition

General Information of This Drug (ID: DMC7E5X)

Drug Name
T89   DMC7E5X
Synonyms
2-Propanone, 1-(5-nitro-2H-tetrazol-2-yl)-; 131394-19-9; 1-(5-nitro-1,2,3,4-tetraazol-2-yl)acetone; ZERO/000247; AC1LOTQU; ACMC-20mu2z; 2-acetonyl-5-nitrotetrazole; CTK0C0970; DTXSID40361521; MolPort-001-904-996; ZINC1084291; STK760073; SBB000169; AKOS000558886; MCULE-5436124308; 1-(5-nitrotetrazol-2-yl)propan-2-one; 2-(2-Oxopropyl)-5-nitro-2H-tetrazole; ST026974; ST023819; BAS 01313849; 1-(5-Nitro-tetrazol-2-yl)-propan-2-one; EU-0085349; 1-(5-nitro-2H-tetrazol-2-yl)propan-2-one; SR-01000523987; SR-01000523987-1
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Multiple myeloma DISEWP9B 2A83 Phase 3 [1]
Angina pectoris DISCLMC4 BA40 Phase 3 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01659580) Phase III Trial of Dantonic (T89) Capsule to Prevent and Treat Stable Angina. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)